Thermo Fisher Scientific Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended July 1, 2023. Thermo Fisher supplies life-sciences research, analytical, diagnostic, laboratory and biopharma products and services through four reportable segments. Unless noted otherwise, amounts are in U.S. dollars.
Financial performance
| Metric | Q2 2023 | Q2 2022 | First six months 2023 | First six months 2022 |
|---|---|---|---|---|
| Revenue | $10.687B | $10.970B | $21.397B | $22.788B |
| GAAP operating income | $1.578B | $2.001B | $3.141B | $4.822B |
| GAAP operating margin | 14.8% | 18.2% | 14.7% | 21.2% |
| Adjusted operating margin (non-GAAP) | 22.2% | 23.7% | 22.0% | 26.6% |
| Net income attributable to Thermo Fisher | $1.361B | $1.664B | $2.650B | $3.879B |
| Diluted GAAP EPS | $3.51 | $4.22 | $6.83 | $9.83 |
| Adjusted EPS (non-GAAP) | $5.15 | $5.51 | $10.18 | $12.76 |
- Quarterly revenue declined 3% year over year; six-month revenue declined 6%. Organic revenue growth was negative 3% and negative 6%, respectively.
- Q2 product revenue was $6.271B, down from $7.003B; service revenue rose to $4.416B from $3.967B.
- For the first six months, operating cash flow was $2.269B (prior year $3.730B), and free cash flow, a non-GAAP measure, was $1.537B (prior year $2.598B). Investing activities used $3.585B, including $2.751B for acquisitions; financing activities used $4.049B.
- At July 1, cash and cash equivalents were $3.133B, versus $8.524B at year-end 2022. Total debt was approximately $34.008B; $4.814B was classified as short-term/current maturities. The $5.0B revolving facility had no borrowings outstanding, and the company reported compliance with debt covenants.
Material changes and business drivers
- Life Sciences Solutions revenue fell 25% in Q2, primarily from lower COVID-related demand; segment income fell 38%. Specialty Diagnostics revenue was roughly flat as underlying businesses partly offset weaker COVID-testing demand.
- Analytical Instruments revenue grew 9% in Q2, with strength across businesses, particularly electron microscopy. Laboratory Products and Biopharma Services revenue grew 5%, supported mainly by clinical research and pharma services.
- Management said COVID-19 testing product sales were $0.08B in Q2 2023 versus $0.63B in Q2 2022, and $0.22B versus $2.31B for the first six months.
- Management cited lower COVID-related revenue, strategic growth investments and currency effects as pressures on margins, partly offset by productivity improvements and pricing. The company also described challenging macroeconomic conditions and a slow recovery in China; academic and government demand was strong.
Outlook, unusual items and risks
- No clear full-year revenue or EPS guidance is provided in the supplied filing text. Management expected 2023 GAAP tax rate of 5%–7%, adjusted tax rate of approximately 10%, cash income-tax payments of approximately $1.40B and net capital expenditures of approximately $1.7B.
- Restructuring and other costs were $183M in Q2 and $295M in the first six months, including severance, facility consolidations and asset impairments. Actions affected approximately 3% of the workforce. As of August 4, the company identified about $85M of additional restructuring charges, primarily expected in 2023.
- The January acquisition of The Binding Site had a purchase price of $2.699B. A separate agreement to acquire CorEvitas for approximately $0.91B in cash was expected to close by year-end 2023, subject to customary conditions and regulatory approvals.
- GAAP tax expense was unusually low: the six-month effective rate was 3.5%, with management citing tax-planning benefits, including a $91M net benefit from an intercompany debt refinancing-related foreign-exchange loss and a $144M benefit from an intra-entity transaction.
- Risks include uncertain demand and customer spending, macroeconomic and China conditions, currency movements, acquisition integration and expected benefits, regulatory matters, and environmental, product-liability and other litigation exposures. The company said unfavorable outcomes could exceed current accruals; it did not identify material changes to disclosed environmental or litigation accruals.
Key facts for investors to verify
- Whether demand stabilizes as COVID-related sales continue to normalize, and how segment trends evolve—especially in Life Sciences Solutions and Specialty Diagnostics.
- Whether operating cash flow and free cash flow recover from the first-half decline and how working-capital timing affects cash generation.
- Debt maturities, refinancing costs and interest expense, which rose year over year amid acquisition and share-repurchase financing.
- Actual restructuring charges versus the additional approximately $85M identified, and the resulting savings and margin impact.
- CorEvitas closing, purchase accounting and integration, as well as the expected contribution from The Binding Site.
- Full-year performance against the disclosed tax and capital-expenditure expectations; the filing text does not provide clear full-year revenue or EPS guidance.